{"article_title": "DeMuth and DeMuth: The FDA Nixes a Pathbreaking Drug for MS", "article_keywords": ["fda", "treating", "shown", "used", "sclerosisunder", "union", "university", "drug", "nixes", "pathbreaking", "ms", "subsidiary", "sanofi", "demuth", "today", "treatment"], "article_url": "http://www.wsj.com/articles/SB10001424052702303465004579322403405913292", "article_text": "Alemtuzumab is used today as an intravenous treatment for a form of leukemia. But 20 years of research centered at Cambridge University also has shown that the action of this drug\u2014depleting immune cells that become misdirected and attack one's own body\u2014is effective in treating multiple sclerosis.\n\nUnder the brand name Lemtrada (a product of Sanofi and its U.S. subsidiary Genzyme), the drug has been approved in recent months for treating MS in 30 countries, including Canada, Australia and all members of the European Union....", "article_metadata": {"article.template": "snippet", "article.created": "2014-01-17T00:12:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "In The Wall Street Journal, Christopher DeMuth Sr. and Christopher DeMuth Jr. write that 30 developed nations have approved Lemtrada. The U.S. refusal to do so shows the need for regulatory reform.", "title": "The FDA Nixes a Pathbreaking Drug for MS", "image": {"src": "https://si.wsj.net/public/resources/images/BN-BD123_demuth_G_20140116132345.jpg", "alt": "DeMuth and DeMuth: The FDA Nixes a Pathbreaking Drug for MS", "identifier": "https://si.wsj.net/public/resources/images/BN-BD123_demuth_D_20140116132345.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702303465004579322403405913292&headline=DeMuth%20and%20DeMuth%3A%20The%20FDA%20Nixes%20a%20Pathbreaking%20Drug%20for%20MS&weburl=http://www.wsj.com/articles/SB10001424052702303465004579322403405913292"}}, "page.site.product": "WSJ", "keywords": "Sanofi,SAN.FR,SNY,regulation,government policy,regulatory bodies,new products,services,research,development,new product approvals,corporate,industrial news,official trials,tests,cancer,political,general news,health,leukemia,medical conditions,politics,international relations,domestic politics,medical treatments,procedures,government bodies,executive branch,human services department,commentaries,opinions,pharmaceuticals,health care,life sciences", "news_keywords": "Sanofi,SAN.FR,SNY,regulation,government policy,regulatory bodies,new products,services,research,development", "article.headline": "DeMuth and DeMuth: The FDA Nixes a Pathbreaking Drug for MS", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-BD123_demuth_E_20140116132345.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-BD123_demuth_D_20140116132345.jpg"}}, "description": "In The Wall Street Journal, Christopher DeMuth Sr. and Christopher DeMuth Jr. write that 30 developed nations have approved Lemtrada. The U.S. refusal to do so shows the need for regulatory reform.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702303465004579322403405913292&headline=DeMuth%20and%20DeMuth%3A%20The%20FDA%20Nixes%20a%20Pathbreaking%20Drug%20for%20MS&weburl=http://www.wsj.com/articles/SB10001424052702303465004579322403405913292", "user.type": "nonsubscriber", "article.page": "Opinion", "page.content.format": "responsive", "article.summary": "In The Wall Street Journal, Christopher DeMuth Sr. and Christopher DeMuth Jr. write that 30 developed nations have approved Lemtrada. The U.S. refusal to do so shows the need for regulatory reform.", "page.site": "wsj", "testkeys": "C", "article.published": "2014-01-17T00:12:00.000Z", "dj.asn": "i-b925", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 1156}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "In The Wall Street Journal, Christopher DeMuth Sr. and Christopher DeMuth Jr. write that 30 developed nations have approved Lemtrada. The U.S. refusal to do so shows the need for regulatory reform.", "title": "The FDA Nixes a Pathbreaking Drug for MS", "url": "http://www.wsj.com/articles/SB10001424052702303465004579322403405913292", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-BD123_demuth_G_20140116132345.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Christopher DeMuth Sr. And Christopher DeMuth Jr.", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "The FDA Nixes a Pathbreaking Drug for MS", "article.type": "Commentary (U.S.)", "article.id": "SB10001424052702303465004579322403405913292", "user.exp": "default", "article.updated": "2014-01-17T00:12:00.000Z"}, "_id": "\"57477af46914bd0286fe084b\"", "article_summary": "Alemtuzumab is used today as an intravenous treatment for a form of leukemia.\nUnder the brand name Lemtrada (a product of Sanofi and its U.S. subsidiary Genzyme), the drug has been approved in recent months for treating MS in 30 countries, including Canada, Australia and all members of the European Union....\nBut 20 years of research centered at Cambridge University also has shown that the action of this drug\u2014depleting immune cells that become misdirected and attack one's own body\u2014is effective in treating multiple sclerosis."}